DSpace About DSpace Software 日本語

01 奈良県立医科大学 >
011 医学部 >
0111 学術雑誌論文 >
01111 医学科 >

Please use this identifier to cite or link to this item: http://hdl.handle.net/10564/2320

Title: Combination of Interferon-β and the Angiotensin-Converting Enzyme Inhibitor, Perindopril, Attenuates Murine Hepatocellular Carcinoma Development and Angiogenesis.
Authors: Noguchi, Ryuichi
Yoshiji, Hitoshi
Kuriyama, Shigeki
Yoshii, Junichi
Ikenaka, Yasuhide
Yanase, Koji
Namisaki, Tadashi
Kitade, Mitsuteru
Yamazaki, Masaharu
Mitoro, Akira
Tsujinoue, Hirohisa
Imazu, Hiroo
Masaki, Tsutomu
Fukui, Hiroshi
Keywords: VEGF
ACE inhibitor
Issue Date: 1-Dec-2003
Publisher: American Association for Cancer Research
Citation: Clinical Cancer Research Vol.9 No.16 pp.6038–6045
Abstract: PURPOSE: Angiogenesis is now recognized as a crucial step in the development of tumors, including hepatocellular carcinoma (HCC). The aim of this study was to elucidate the combined effect of the clinically used angiotensin I-converting enzyme (ACE) inhibitor, perindopril (PE), and IFN-beta on the development and angiogenesis of murine HCC at clinically comparable low doses. EXPERIMENTAL DESIGN: PE and IFN were administered at doses of 2 mg/kg/day and 1 x 10(4) IU/twice a week, respectively. RESULTS: Both PE and IFN significantly suppressed HCC development and inhibited neovascularization in the tumor, although the effect of low-dose IFN was weaker than that of PE. A combination regimen of PE plus IFN was effective; IFN significantly augmented the tumoricidal effect of PE. These inhibitory effects of PE plus IFN could be detected even on established tumors. The potent angiogenic factor, vascular endothelial growth factor, was markedly suppressed by combined treatment with PE and IFN, whereas these agents produced a marked increase of apoptosis in the tumor. The in vitro studies exhibited that PE and IFN inhibited endothelial cell tubular formation. IFN also suppressed endothelial cell proliferation, whereas neither IFN nor PE showed any inhibitory effect on proliferation of HCC cells. CONCLUSION: The combination treatment of PE and IFN at clinically comparable low doses could inhibit HCC development and angiogenesis and suppress vascular endothelial growth factor as well. Because both agents are widely used in clinical practice, this combination regimen may represent a potential new strategy for HCC therapy in the future.
Description: The definitive version is available at " http://clincancerres.aacrjournals.org/content/9/16/6038 "
URI: http://hdl.handle.net/10564/2320
ISSN: 10780432
Appears in Collections:01111 医学科

Files in This Item:

File Description SizeFormat
Clinical_Cancer_Research_9(16)_6038–6045.pdf1.84 MBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.


Valid XHTML 1.0! DSpace Software Copyright © 2002-2010  Duraspace - Feedback